← board
BIAFW
distress 8/10 · high distress / dilution risk$0.08-73%today-73% from 52w high
Lead: lung cancer detection · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
-84%
Price & events
-69.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-72.9%
1D
-72.9%
1W
-72.9%
1M
-72.9%
3M
—
6M
—
1Y
—
2Y
—
5Y
-69.3%
All
Overview
- Market Cap
- $362.34K
- Volume
- 1.90K
- 52 Week Range
- $0.08 – $0.29
- Total Shares
- 4.53M
- Float Shares
- 4.42M
- RVOL
- 30.00x
- Beta
- -1.11
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- April 16, 2026conferencedata presentationsecondaryCyPath Lung · CyPath Lung test will be featured at the invitation-only 'Advances in Early Lung Cancer Detection' symposium at the Cleveland Clinic.SEC 8-K
- planned 2025 milestonestrial initiationsecondaryCyPath® Lung · starting enrollment for FDA pivotal trialSEC 8-K
- 2025-07-15fda agreementCyPath® Lung · Received notification of allowance from CNIPA for patent covering CyPath® Lung flow cytometry method.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — lung cancer detection
- none identified
Recent news
- 2026-07-22bioAffinity and Pictor partner on lung inflammation diagnostics - TipRanks
- 2026-07-07CyPath Lung sales top prior quarter as bioAffinity sees 200% growth - Stock Titan
- 2026-07-05bioAffinity Technologies (BIAF) Holds Near Support as Trading Volume Remains Elevated - Naked POC - dars.gov.et
- 2026-06-22Skin cancer cells die in bioAffinity lab test, healthy cells spared - Stock Titan
- 2026-06-15bioAffinity Technologies Warrant (BIAFW) Holds Steady at $0.16 as Trading Remains Quiet - GEX Level - dars.gov.et
- 2026-03-25BioAffinity’s CyPath Lung Tests Signal Powerful Growth for 2026 - timothysykes.com
- 2026-03-13bioAffinity Technologies, Inc. (BIAF) Stock: Soars 123% as CyPath Lung Growth and 2026 Expansion Plans Boost Investor Confidence - parameter.io
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.